High Tide Pre-Announces Stellar Q3 2026 Guidance and Record German Distribution, Beating Analyst Forecasts

What happened

High Tide Inc. released preliminary Q3 FY2026 guidance showing revenue of $195-200 million and adjusted EBITDA of $15.2-16.5 million, well above consensus estimates of around $185 million revenue and $14.4 million EBITDA. The company also reported that its Remexian subsidiary distributed a record 10 tonnes of medical cannabis flower in Germany during the quarter, signaling rapid international scale. These figures indicate that Canadian retail same-store sales momentum and cost controls remain strong, while German volumes are accelerating faster than modeled in the base case. The beat bolsters management’s self-funding narrative by demonstrating that growth is converting to higher profitability. However, the full quarterly cash flow statement and any update on ATM equity usage will ultimately determine whether this operational strength translates to per-share value or merely masks growing working-capital intensity.

Implication

Preliminary Q3 figures position High Tide to achieve annualized EBITDA above $50 million, which would support a bull-case valuation of $4.60/share if sustained without equity issuance. The Remexian volume surge to 10 tonnes per quarter amplifies the German growth story but also escalates the cash conversion gap flagged in the master report, as supplier deposits and receivables may rise proportionally. Investors should treat the guidance as a strong positive signal but await the full quarterly filing to confirm positive operating cash flow and continued ATM inactivity before upgrading conviction. Current prices near $2.57 reflect a discount to the base case of $3.10, and a pullback toward the attractive entry of $2.30 would offer a more asymmetric opportunity. Trimming above $3.60 becomes less urgent if the bull case probability has increased, but discipline is warranted until cash flow is verified.

Thesis delta

The Q3 guidance beat and record German distribution shift thesis probabilities moderately toward the bull case, as the path to $4.60 becomes demonstrable if cash generation holds. However, the central risk—whether Remexian scaling forces ATM equity issuance—remains unresolved until full cash flow and share count data are reported, keeping the investment thesis contingent on operational cash flow positivity.